Description

NOTA-P2-RM26 is a synthetic peptide designed for high-affinity antagonism of the gastrin-releasing peptide receptor (GRPR/BB2), a molecular target prominently expressed in prostate cancer cells. With a purity of 98.19% and produced in a GMP-certified facility, NOTA-P2-RM26 is optimized for laboratory research applications in oncological imaging, peptide-based diagnostics, and receptor-targeted molecular studies.

The peptide is derived from Bombesin analogs and retains structural modifications that enhance receptor specificity while minimizing off-target interactions. In vitro studies demonstrate that NOTA-P2-RM26 binds selectively to GRPR-expressing cells, providing a reliable tool for preclinical imaging experiments. When radiolabeled with 111In or 68Ga, it enables non-invasive visualization of prostate tumors through PET or SPECT/CT imaging, facilitating quantification of tumor receptor density, pharmacokinetics, and biodistribution.

NOTA-P2-RM26’s structure incorporates the NOTA chelator, which allows stable and efficient coordination with metallic radionuclides. This radiolabeling versatility supports dual-modality imaging studies and the development of theranostic strategies. The peptide’s antagonist activity ensures minimal receptor internalization, preserving extracellular availability for imaging and enhancing signal detection in vivo.

Beyond imaging, NOTA-P2-RM26 serves as a molecular tool for understanding GRPR signaling pathways in prostate cancer cells. GRPR overexpression is implicated in tumor growth, progression, and metastasis, and this peptide provides a platform for investigating receptor pharmacology, ligand-receptor interactions, and the impact of GRPR antagonism on tumor cell behavior. Its compatibility with both 111In and 68Ga facilitates detailed pharmacokinetic studies and allows researchers to explore novel imaging protocols for translational oncology research.

The peptide exhibits excellent solubility and stability under laboratory storage conditions, ensuring reproducible results across multiple experimental setups. NOTA-P2-RM26’s combination of high receptor specificity, radiolabeling flexibility, and GMP-level manufacturing makes it an indispensable reagent for advanced prostate cancer imaging studies and preclinical receptor-targeted research.

Product Specifications

Mechanism of Action & Research Applications

NOTA-P2-RM26 acts as a high-affinity antagonist of the gastrin-releasing peptide receptor (GRPR/BB2). GRPR is overexpressed in many prostate cancers and mediates growth-promoting signaling pathways when activated by endogenous ligands such as bombesin. As an antagonist, NOTA-P2-RM26 binds to GRPR without activating the receptor, effectively blocking endogenous ligand binding and preventing downstream signaling.

The inclusion of the NOTA chelator in its structure allows stable radiolabeling with metallic isotopes like 111In for SPECT imaging or 68Ga for PET imaging. Upon administration in experimental models, radiolabeled NOTA-P2-RM26 selectively accumulates in GRPR-expressing tumor tissues, providing a highly sensitive and specific signal for imaging studies. The antagonist activity ensures that receptor internalization is minimal, maintaining extracellular availability and enhancing imaging contrast.

Research applications for NOTA-P2-RM26 are broad:

1. Prostate Cancer Imaging: Enables preclinical PET and SPECT/CT studies to quantify tumor receptor expression and monitor tumor progression.

2. Receptor Pharmacology Studies: Serves as a molecular probe to explore GRPR signaling, receptor-ligand interactions, and antagonism effects in vitro.

3. Theranostic Development: Facilitates studies integrating diagnostic imaging with potential therapeutic radionuclides for receptor-targeted therapy.

4. Pharmacokinetic and Biodistribution Research: Supports experiments evaluating peptide stability, circulation half-life, and tumor-specific accumulation.

5. Translational Oncology Research: Provides a preclinical platform for developing GRPR-targeted imaging and therapeutic agents.

The peptide can be used in vitro with GRPR-positive cell lines to examine receptor binding kinetics, competition assays, and ligand displacement studies. In vivo, it provides a reliable tool for imaging tumor localization, monitoring tumor progression, and evaluating new GRPR-targeted therapeutics. Its dual compatibility with 111In and 68Ga allows comparison of PET versus SPECT modalities in experimental imaging studies.

Side Effects (For Reference in Models)

In experimental laboratory use, NOTA-P2-RM26 is generally well-tolerated in cell culture and animal models. Potential effects may include mild receptor-related alterations in cellular signaling at high concentrations or transient nonspecific binding in tissues. Standard laboratory safety protocols should be observed, and the peptide should not be used for human or veterinary purposes.

Disclaimer

NOTA-P2-RM26 is intended for laboratory research purposes only. It is not for human or veterinary use, diagnostic procedures, or clinical applications. Researchers must follow institutional safety guidelines when handling this peptide.

 Keywords

NOTA-P2-RM26, GRPR antagonist, Bombesin analog, prostate cancer imaging, PET imaging peptide, SPECT imaging peptide, 68Ga radiolabeled peptide, 111In peptide, prostate cancer research peptide, receptor-targeted imaging, laboratory GRPR antagonist, peptide radiopharmaceutical research, GMP peptide supplier, synthetic GRPR ligand, preclinical imaging peptide,CAS : 1446005-10-2